CytomX Therapeutics (CTMX) executive compensation, 2026 proxy

Sean A. McCarthy, D. Phil., Chief Executive Officer and Chairman of the Board of Directors, was paid $4.7M in 2025, up 170% from $1.8M the year before.

Filed
April 30, 2026
Annual meeting
June 17, 2026
Pay year
2025
Named executives
3
CEO total pay
$4.7M+170% vs prior year
CEO pay in equity
70%$3.3M in awards
CEO 2025 Total Compensation
$4,738,495Reported in summary compensation table
CEO 2024 Total Compensation
$1,752,802Prior year figure
CEO Annual Cash Bonus
$546,8952025 performance-based incentive

How Phil. was paid

$4.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary14%Stock awards24%Option awards46%Non-equity incentive16%All other compensation0%

Named executive officers

ExecutiveTotal
Sean A. McCarthy, D. Phil.Chief Executive Officer and Chairman of the Board of Directors$4,738,495
Chris OgdenSenior Vice President, and Chief Financial Officer$1,542,631
Rachael LesterSenior Vice President and Chief Business Officer$2,234,874

What changed and why

  • $4.7MCEO Sean A. McCarthy received total compensation of $4,738,495 in 2025, an increase from $1,752,802 in 2024.
  • $547KThe CEO's non-equity incentive plan compensation included $546,895 for annual performance and $202,587 from a milestone award.
  • $2.2MRachael Lester joined as Senior Vice President and Chief Business Officer in October 2025 with a total compensation of $2,234,874.
  • $10.6MCompensation actually paid to the PEO was calculated at $10,636,158 for fiscal 2025 reflecting equity value changes.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.